Avadel Pharmaceuticals PLC (AVDL)

NASDAQ: AVDL · IEX Real-Time Price · USD
6.87
-0.06 (-0.87%)
Aug 15, 2022 4:00 PM EDT - Market closed
-0.87%
Market Cap 410.78M
Revenue (ttm) n/a
Net Income (ttm) -134.17M
Shares Out 59.79M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 617,771
Open 7.00
Previous Close 6.93
Day's Range 6.82 - 7.22
52-Week Range 1.05 - 11.59
Beta 1.51
Analysts Buy
Price Target 9.95 (+44.8%)
Earnings Date Aug 9, 2022

About AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. [Read more...]

Industry Pharmaceuticals
IPO Date Jun 7, 1996
CEO Gregory Divis
Employees 66
Stock Exchange NASDAQ
Ticker Symbol AVDL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for AVDL stock is "Buy." The 12-month stock price forecast is 9.95, which is an increase of 44.83% from the latest price.

Price Target
$9.95
(44.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results

DUBLIN, Ireland, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate...

Wall Street Analysts Think Avadel (AVDL) Could Surge 106%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 105.6% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive...

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter Financial Results on August 9

DUBLIN, Ireland, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it wi...

Avadel Pharmaceuticals Announces Tentative Approval of LUMRYZ™ (sodium oxybate) extended-release oral suspension

- Validates the safety profile and clinical efficacy of LUMRYZ

Avadel Cuts Workforce, Optimizes Cost Structure To Support This

Avadel Pharmaceuticals plc (NASDAQ: AVDL) announced its steps to explore every available pathway to accelerate the FDA approval of its lead drug candidate, FT218, before June 2023.  Avadel has received ...

Avadel Pharmaceuticals Provides Corporate Update

DUBLIN, Ireland, June 29, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the steps ...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avadel Pharmaceuticals plc - AVDL

New York, New York--(Newsfile Corp. - June 15, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc (""or the "Company") (NASDAQ: AVDL). Such investors are ...

Avadel Pharmaceuticals and the American Academy of Sleep Medicine Foundation Announce an Exclusive Collaboration on t...

DUBLIN, Ireland, June 03, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it en...

Avadel's stock falls 21% after disclosing new FDA request for experimental narcolepsy drug

Shares of Avadel Pharmaceuticals PLC AVDL, -8.15% tumbled 21.6% in premarket trading on Thursday after the company said in a securities filing that the Food and Drug Administration requested additional ...

Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Greg D...

What Does HC Wainwright Have To Say On Avadel's Narcolepsy Candidate's Potential Approval

Avadel Pharmaceuticals PLC (NASDAQ: AVDL) reported 1Q results and provided updated color on the U.S. marketing application for FT218. FT218 is once nightly sodium oxybate for narcolepsy, which would com...

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

DUBLIN, Ireland, May 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate ...

Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter Financial Results on May 9

DUBLIN, Ireland, May 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it wil...

Why Avadel Pharmaceuticals Stock Is Skyrocketing Today

The stock is rebounding from Monday's sell-off after a public statement from the company.

Avadel Pharmaceuticals Provides Comment on Recent Trading Activity

DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a statemen...

Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neuro...

DUBLIN, Ireland, April 25, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the prese...

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Exec...

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

DUBLIN, Ireland, March 17, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today provided a corporate update and annou...

Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi R...

Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among ...

DUBLIN, Ireland, March 11, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data will be presented ...

Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Exec...

Avadel to Present New Clinical Data at World Sleep 2022

DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present eight poste...

Avadel Pharmaceuticals Appoints Dr. Douglas Williamson as Chief Medical Officer

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas W...

Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Execu...

Do Options Traders Know Something About Avadel (AVDL) Stock We Don't?

Investors need to pay close attention to Avadel (AVDL) stock based on the movements in the options market lately.